Earnings

The company reported earnings of $4.32 billion, or $1.53 per share, down from $4.73 billion, or $1.64 per share, last year. Excluding special items, earnings were $1.56 per share – above analysts’ view of $1.54.

Revenue
Revenue declined 4.1% to $17.37 billion from $18.12 billion last year. Analysts expected to see revenue of $17.31 billion.

Outlook
Looking ahead, JNJ now expects to see FY2015 EPS between $6.04 and $6.19. Previously, the company expected to see EPS between $6.12 and $6.27 per share. Analysts expect to see EPS of $6.16.

The company has a large cash stockpile which it may plan to use for future acquisitions to grow more profitable businesses. Last month, JNJ failed to acquire Pharmacyclics, but there could be more deals in the pipeline.

Investors interested in JNJ may be interested in the funds listed below. These funds currently have the largest stakes in the company.

The funds listed above allow investors to gain exposure to JNJ while remaining diversified. Investors interested in JNJ may also be interested in Pfizer (PFE) and Merck (MRK).